Znanstveni rad - Pregledni rad
Safety and efficacy of dual antiplatelet therapy after percutaneous coronary interventions in patients with end-stage liver disease
World Journal of Cardiology, 13 (2021), 11; 599-607. https://doi.org/10.4330/wjc.v13.i11.599

Ostojić, Zvonimir; Ostojić, Ana; Bulum, Joško; Mrzljak, Anna

Citirajte ovaj rad

Ostojić, Z., Ostojić, A., Bulum, J. i Mrzljak, A. (2021). Safety and efficacy of dual antiplatelet therapy after percutaneous coronary interventions in patients with end-stage liver disease. World Journal of Cardiology, 13. (11), 599-607. doi: 10.4330/wjc.v13.i11.599

Ostojić, Zvonimir, et al. "Safety and efficacy of dual antiplatelet therapy after percutaneous coronary interventions in patients with end-stage liver disease." World Journal of Cardiology, vol. 13, br. 11, 2021, str. 599-607. https://doi.org/10.4330/wjc.v13.i11.599

Ostojić, Zvonimir, Ana Ostojić, Joško Bulum i Anna Mrzljak. "Safety and efficacy of dual antiplatelet therapy after percutaneous coronary interventions in patients with end-stage liver disease." World Journal of Cardiology 13, br. 11 (2021): 599-607. https://doi.org/10.4330/wjc.v13.i11.599

Ostojić, Z., et al. (2021) 'Safety and efficacy of dual antiplatelet therapy after percutaneous coronary interventions in patients with end-stage liver disease', World Journal of Cardiology, 13(11), str. 599-607. doi: 10.4330/wjc.v13.i11.599

Ostojić Z, Ostojić A, Bulum J, Mrzljak A. Safety and efficacy of dual antiplatelet therapy after percutaneous coronary interventions in patients with end-stage liver disease. World Journal of Cardiology [Internet]. 26.11.2021. [pristupljeno 28.06.2022.];13(11):599-607. doi: 10.4330/wjc.v13.i11.599

Z. Ostojić, A. Ostojić, J. Bulum i A. Mrzljak, "Safety and efficacy of dual antiplatelet therapy after percutaneous coronary interventions in patients with end-stage liver disease", World Journal of Cardiology, vol. 13, br. 11, str. 599-607, Studeni 2021. [Online]. Dostupno na: https://urn.nsk.hr/urn:nbn:hr:105:130088. [Citirano: 28.06.2022.]

Prijavite se u repozitorij kako biste mogli spremiti objekt u svoju listu.